Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | CA4 | P22748 | 4/20 | 0.56 |
| ▸ | CA9 | Q16790 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491620 | 0.92 | CA1 (0.65) | CA1CA2CA4CA9LMNA | |
| SCHEMBL14714339 | 0.92 | CA1 (0.65) | CA1CA2CA4CA9LMNA | |
| SCHEMBL15279940 | 0.92 | CA1 (0.65) | CA1CA2CA4CA9LMNA | |
| SCHEMBL14032987 | 0.87 | LMNA (0.52) | CA1CA2CA4CA9LMNA | |
| SCHEMBL28429511 | 0.86 | SIGMAR1 (0.54) | CA1CA2CA4CA9LMNA | |
| SCHEMBL3496353 | 0.86 | SIGMAR1 (0.54) | CA1CA2CA4CA9LMNA | |
| SCHEMBL28429512 | 0.86 | SIGMAR1 (0.54) | CA1CA2CA4CA9LMNA | |
| SCHEMBL28737728 | 0.85 | CA1 (0.57) | CA1CA2CA4CA9LMNA | |
| SCHEMBL28737727 | 0.85 | CA1 (0.57) | CA1CA2CA4CA9LMNA | |
| SCHEMBL1713773 | 0.85 | CA1 (0.52) | CA1CA2CA4CA9AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CA1 2275/4885CA2 218/4885CA4 296/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CA1 2275/4885CA2 218/4885CA4 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.